Share

November 2021; 8 (6) ArticleOpen Access

Neurofilament Light in CSF and Plasma Is a Marker of Neuronal Damage in HTLV-1–Associated Myelopathy and Correlates With Neuroinflammation

Carolina Rosadas, Henrik Zetterberg, Amanda Heslegrave, Jana Haddow, Mina Borisova, Graham P. Taylor
First published October 5, 2021, DOI: https://doi.org/10.1212/NXI.0000000000001090
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
628

Share

Article Information

vol. 8 no. 6 e1090
DOI: 
https://doi.org/10.1212/NXI.0000000000001090
PubMed: 
34611039
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received October 25, 2020
  • Accepted in final form August 10, 2021
  • First Published October 5, 2021.
Copyright & Usage: 
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Author Disclosures

    1. Carolina Rosadas, PhD,
    2. Henrik Zetterberg, Prof, MD, PhD (henrik.zetterberg{at}clinchem.gu.se),
    3. Amanda Heslegrave, PhD (a.heslegrave{at}ucl.ac.uk),
    4. Jana Haddow, MSc (jana.haddow{at}nhs.net),
    5. Mina Borisova, BSc (Hons) (m.borisova{at}ucl.ac.uk) and
    6. Graham P. Taylor, MB, DSc (g.p.taylor{at}imperial.ac.uk)
  1. Carolina Rosadas, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Henrik Zetterberg, Prof, MD, PhD (henrik.zetterberg{at}clinchem.gu.se),
    3. Scientific Advisory Boards:

    1. HZ has served at scientific advisory boards for Alector, Eisai, Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, Nervgen, AZTherapies, CogRx and Red Abbey Labs.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. HZ has given lectures in symposia sponsored by Cellectricon, Fujirebio, Biogen and Alzecure.

    Editorial Boards:

    1. Journal of Alzheimer's Disease, Associate Editor Alzheimer's & Dementia, Associate Editor DADM, Associate Senior Editor Molecular and Cellular Neuroscience, Editor Scandinavian Journal of Clinical and Laboratory Investigation, Editor

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. HZ is co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (not related to submitted work).

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) Swedish State Support for Clinical Research (#ALFGBG- 720931) and (2) the Knut and Alice Wallenberg Foundation (Wallenberg Scholar).

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Amanda Heslegrave, PhD (a.heslegrave{at}ucl.ac.uk),
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Jana Haddow, MSc (jana.haddow{at}nhs.net),
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Mina Borisova, BSc (Hons) (m.borisova{at}ucl.ac.uk) and
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Graham P. Taylor, MB, DSc (g.p.taylor{at}imperial.ac.uk)
    7. Scientific Advisory Boards:

    1. Unitaid, DSMB for a non-commercial study of the treatment of HIV infection in pregnant women

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. 1) World Health Organisation, travel expenses to attend working party on HTLV infection

    Editorial Boards:

    1. PLoS NTD, associate editor 2020-21 Frontiers, edition editor 2019-

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. MRC-Leuka. Principle Investigator Imperial BRC. Principle Investigator UKRI, Co-Investigator March of Dimes, Co-investigator

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Section of Virology (C.R., G.P.T.), Department of Infectious Disease, Imperial College London; UK Dementia Research Institute at UCL (H.Z., A.H., M.B.); Department of Neurodegenerative Disease (H.Z., A.H., M.B.) at UCL Institute of Neurology, London, UK; Clinical Neurochemistry Laboratory (H.Z.), Sahlgrenska University Hospital; Department of Psychiatry and Neurochemistry (H.Z.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; and National Centre for Human Retrovirology (J.H., G.P.T.), St. Mary's Hospital, Imperial College Healthcare NHS Trust, London, UK.
  1. Correspondence
    Prof. Taylor g.p.taylor{at}imperial.ac.uk

Article usage

Article usage: October 2021 to October 2023

AbstractFullPdfSource
Oct 202113625158Highwire
Nov 2021211332Highwire
Dec 202167520Highwire
Jan 2022410233Highwire
Feb 202226039Highwire
Mar 202214528Highwire
Apr 202264730Highwire
May 202223424Highwire
Jun 202224219Highwire
Jul 202214415Highwire
Aug 202233918Highwire
Sep 202274719Highwire
Oct 202233426Highwire
Nov 202266024Highwire
Dec 202232710Highwire
Jan 202344313Highwire
Feb 202323318Highwire
Mar 202301910Highwire
Apr 202331518Highwire
May 202351212Highwire
Jun 202331714Highwire
Jul 202322716Highwire
Aug 20232186Highwire
Sep 202311912Highwire
Oct 202322214Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me